Hematologic Malignancies and Cellular Therapy

Hematologic Malignancies and Cellular Therapy

64 items identified
ALX148 in combo with Aza in patients with higher risk MDS (Myelodysplastic Syndrome)
ABBV-453 for Relapsed or Refractory Multiple Myeloma
AbbVie: M15-538 (Multiple Myeloma)
AbbVie: Ph 1b Open of Eftozanermin Alfa (Relapsed/Refractory Multiple Myeloma)
ACT in HCT (Stem Cell Transplant)
AG120-C-001 PH1 in IDH1 Mutation (AML, MDS, other Hematologic Malignancies)
Alexion - ALXN-1210-TMA-313: Thrombotic Microangiopathy (TMA) after a bone marrow transplant
Alexion: Ph3 Danicopan (Paroxysmal Nocturnal Hemoglobinuria)
Alliance A051301 (Large B-Cell Lymphoma)
Alliance A051701 (Lymphoma)
ALVR106 in Treatment of Respiratory Viral Infections After Hematopoietic Stem Cell Transplant
ALX Oncology 148005: I/II of ALX148 in combo with Venetoclax and AZA in AML (Leukemia)
AML Remote Monitoring (Acute Myeloid Leukemia)
Ascentage Pharma PHIb/II APG-115 (Leukemia & Myelodysplastic Syndrome)
ATARA_ALLELE_PTLD (Post-Transplant Lymphoproliferative Disease)
BBI: TP-3654 in Patients with Myelofibrosis
BMT CTN 1705 (Graft-versus-Host Disease)
Caelum: Ph3 (Cardiac Amyloidosis)
Caelum: Ph3 of CAEL-101 (Cardiac Amyloidosis)
Calaspargase Pegol in Adults w/Untreated, Ph-negative B-cell and T cell Acute Lymphoblastic Leukemia
Catapult: Ph1a/b CAP-100 (Chronic Lymphocytic Leukemia)
Celgene: GC-LTFU-001 (Multiple Myeloma)
CRSP-ONC_001 _PhI_allo_ CART_NHL
CSL Behring: Ph2/3 Randomized D-blinded Alpha-1 AntiTrypsin (AAT) in GVHD HCT (Stem Cell Transplant)
Deverra: Phase 1:DVX201 (Blood Cancers)
DFCI: 16-237 Ph1b PVX-410 in SMM
DSP: Phase 1/2 DSP-5336 in Acute Leukemia with or with MLL or NPM1 mutation
EA9181 (Acute Lymphoblastic Leukemia)
ECOG-ACRIN EA4151 (Mantle Cell Lymphoma)
Entospletinib & Chemo in Newly Diagnosed NPM1-mutated Acute Myeloid Leukemia
Gilead: Ph2 Multi-Arm Study of Magrolimab Combos in patients w/ RRMM
GRN163L vs BAT in MF (Myelofibrosis)
HDM201, MBG453 and venetoclax in Acute Myeloid Leukemia or high risk Myelodysplastic Syndrome
Ichnos: Ph1 Multi Open 2 part Dose Esc / Exp Single Agent ISB 1342 (Multiple Myeloma)
IIT: Cord Blood Attenuates Accelerated Aging after Hematopoietic Stem Cell Transplantation
IIT: Ph2 Home Care Study Autologous Hematopoietic Stem Cell Transplantation
IIT: Ph2 Stem Cell Transplantation Medical Home Care Comparison to Standard Hospital Care
IIT_Hematologic Malignancies Microbiota Biorepository (Stem Cell Transplant Recipients)
INCB 50465-304 Parsaclisib Plus Ruxolitinib in Participants With Myelofibrosis
Iovance_IOV-2001_Ph1_CLL_SLL (Chronic Lymphcytic Leukemia or Small Lymphocytic Leukemia)
Juno (Leukemia and Lymphoma)
Karyopharm: Ph1b/2 Selinexor (Multiple Myeloma)
Kura Oncology Ph1/2A KO-539 in R/R AML
Loxo III: Trial of Fixed Pirtobrutinib + Vene and Rituximab in CLL/SLL (Leukemia)
MB-CART2019.1 DLBCL
Mustang Bio: CAR-T Phase 1/2 MB-102 (Blastic Plasmacytoid Dendritic Cell Neoplasm)
Nektar: NKTR-255 for Hematological Malignancies
Neoimmunetech_NT-I7_Ph1b_R/R_LBCL
Nordic nanovector_PhII_CD37_mAb_radionuclide_FL (Non-Hodgkin Lymphoma)
Novartis Phase II MBG453 (Acute Myeloid Leukemia)